conference banner
Abstract

There is much debate about continuing antipsychotic medication in patients who need it when they become pregnant because benefits must be weighed against potential teratogenic and malformation effects related to antipsychotics themselves. To address this, we conducted a systematic review on the PubMed, PsycINFO and CINHAL databases and the ClinicalTrials.gov register using the following strategy: (toxicity OR teratogenicity OR malformation* OR "birth defect*" OR "congenital abnormality" OR "congenital abnormalities" OR "brain changes" OR "behavioral abnormalities" OR "behavioral abnormalities") AND antipsychotic* AND (pregnancy OR pregnant OR lactation OR delivery OR prenatal OR perinatal OR post-natal OR puerperium) on September 27, 2023. We found 38 studies to be eligible. The oldest was published in 1976, while most articles were recent. Most studies concluded that the antipsychotics, especially the second-generation antipsychotics, were devoid of teratogenic potential, while few studies were inconclusive and recommended replication. Most authoritative articles were from the Boston area, where large databases were implemented to study the malformation potential of psychiatric drugs. Other reliable databases are from Northern European registers. Overall conclusions are that antipsychotics are no more related to malformations than the disorders themselves; most studies recommend that there are no reasons to discontinue antipsychotic medications in pregnancy.

Keywords: Pregnancy, malformations, major, teratogenicity, lactation, antipsychotic drugs, second generation antipsychotics.

Graphical Abstract
[1]
Davies, C.; Segre, G.; Estradé, A.; Radua, J.; De Micheli, A.; Provenzani, U.; Oliver, D.; Salazar de Pablo, G.; Ramella-Cravaro, V.; Besozzi, M.; Dazzan, P.; Miele, M.; Caputo, G.; Spallarossa, C.; Crossland, G.; Ilyas, A.; Spada, G.; Politi, P.; Murray, R.M.; McGuire, P.; Fusar-Poli, P. Prenatal and perinatal risk and protective factors for psychosis: A systematic review and meta-analysis. Lancet Psychiatry, 2020, 7(5), 399-410.
[http://dx.doi.org/10.1016/S2215-0366(20)30057-2] [PMID: 32220288]
[2]
Howard, L.M.; Khalifeh, H. Perinatal mental health: A review of progress and challenges. World Psychiatry, 2020, 19(3), 313-327.
[http://dx.doi.org/10.1002/wps.20769] [PMID: 32931106]
[3]
Orsolini, L.; Sceusa, F.; Pompili, S.; Mauro, A.; Salvi, V.; Volpe, U. Severe and persistent mental illness (SPMI) in pregnancy and breastfeeding: Focus on second-generation long acting injectable antipsychotics. Expert Opin. Drug Saf., 2021, 20(10), 1207-1224.
[http://dx.doi.org/10.1080/14740338.2021.1928634] [PMID: 33966552]
[4]
Wesseloo, R.; Kamperman, A.M.; Bergink, V.; Pop, V.J.M. Thyroid peroxidase antibodies during early gestation and the subsequent risk of first-onset postpartum depression: A prospective cohort study. J. Affect. Disord., 2018, 225, 399-403.
[http://dx.doi.org/10.1016/j.jad.2017.08.058] [PMID: 28850854]
[5]
Valdimarsdóttir, U.; Hultman, C.M.; Harlow, B.; Cnattingius, S.; Sparén, P. Psychotic illness in first-time mothers with no previous psychiatric hospitalizations: A population-based study. PLoS Med., 2009, 6(2), e1000013.
[http://dx.doi.org/10.1371/journal.pmed.1000013] [PMID: 19209952]
[6]
O’Hara, M.W.; Wisner, K.L. Perinatal mental illness: Definition, description and aetiology. Best Pract. Res. Clin. Obstet. Gynaecol., 2014, 28(1), 3-12.
[http://dx.doi.org/10.1016/j.bpobgyn.2013.09.002] [PMID: 24140480]
[7]
Cuomo, A.; Goracci, A.; Fagiolini, A. Aripiprazole use during pregnancy, peripartum and lactation. A systematic literature search and review to inform clinical practice. J. Affect. Disord., 2018, 228, 229-237.
[http://dx.doi.org/10.1016/j.jad.2017.12.021] [PMID: 29275156]
[8]
Winans, E.A. Antipsychotics and Breastfeeding. J. Hum. Lact., 2001, 17(4), 344-347.
[http://dx.doi.org/10.1177/089033440101700408] [PMID: 11847903]
[9]
Conejo-Galindo, J.; Sanz-Giancola, A.; Álvarez-Mon, M.Á.; Ortega, M.Á.; Gutiérrez-Rojas, L.; Lahera, G. Postpartum relapse in patients with bipolar disorder. J. Clin. Med., 2022, 11(14), 3979.
[http://dx.doi.org/10.3390/jcm11143979] [PMID: 35887743]
[10]
Edinoff, A.N.; Sathivadivel, N.; McNeil, S.E.; Ly, A.I.; Kweon, J.; Kelkar, N.; Cornett, E.M.; Kaye, A.M.; Kaye, A.D. Antipsychotic use in pregnancy: Patient mental health challenges, teratogenicity, pregnancy complications, and postnatal risks. Neurol. Int., 2022, 14(1), 62-74.
[http://dx.doi.org/10.3390/neurolint14010005] [PMID: 35076595]
[11]
Munk-Olsen, T.; Laursen, T.M.; Mendelson, T.; Pedersen, C.B.; Mors, O.; Mortensen, P.B. Risks and predictors of readmission for a mental disorder during the postpartum period. Arch. Gen. Psychiatry, 2009, 66(2), 189-195.
[http://dx.doi.org/10.1001/archgenpsychiatry.2008.528] [PMID: 19188541]
[12]
Sprague, J.; Wisner, K.L.; Bogen, D.L. Pharmacotherapy for depression and bipolar disorder during lactation: A framework to aid decision making. Semin. Perinatol., 2020, 44(3), 151224.
[http://dx.doi.org/10.1016/j.semperi.2020.151224] [PMID: 32199600]
[13]
McAllister-Williams, R.H.; Baldwin, D.S.; Cantwell, R.; Easter, A.; Gilvarry, E.; Glover, V.; Green, L.; Gregoire, A.; Howard, L.M.; Jones, I.; Khalifeh, H.; Lingford-Hughes, A.; McDonald, E.; Micali, N.; Pariante, C.M.; Peters, L.; Roberts, A.; Smith, N.C.; Taylor, D.; Wieck, A.; Yates, L.M.; Young, A.H. British association for psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J. Psychopharmacol., 2017, 31(5), 519-552.
[http://dx.doi.org/10.1177/0269881117699361] [PMID: 28440103]
[14]
Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; Chou, R.; Glanville, J.; Grimshaw, J.M.; Hróbjartsson, A.; Lalu, M.M.; Li, T.; Loder, E.W.; Mayo-Wilson, E.; McDonald, S.; McGuinness, L.A.; Stewart, L.A.; Thomas, J.; Tricco, A.C.; Welch, V.A.; Whiting, P.; Moher, D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 2021, 372(71), n71.
[http://dx.doi.org/10.1136/bmj.n71] [PMID: 33782057]
[15]
ROBINS-E Development Group. Higgins, J.; Morgan, R.; Rooney, A.; Taylor, K.; Thayer, K.; Silva, R .; Lemeris, C.; Akl, A.; Arroyave, W.; Bateson, T.; Berkman, N.; Demers, P.; Forastiere, F.; Glenn, B.; Hróbjartsson, A.; Kirrane, E.; LaKind, J.; Luben, T.; Lunn, R.; McAleenan, A.; McGuinness, L.; Meerpohl, J.; Mehta, S.; Nachman, R.; Obbagy, J.; O'Connor, A.; Radke, E.; Savović, J.; Schubauer-Berigan, M.; Schwingl, P.; Schunemann, H.; Shea, B.; Steenland, K.; Stewart, T.; Straif, K.; Tilling, K.; Verbeek, V.; Vermeulen, R.; Viswanathan, M.; Zahm, S.; Sterne, J. Risk Of Bias In Non-randomized Studies of Exposure (ROBINS-E). Launch version, 20 June 2023. Available from: https://www.riskofbias.info/welcome/robins-e-tool (assessed on August 25, 2023.)
[16]
Rieder, R.O.; Rosenthal, D.; Wender, P.; Blumenthal, H. The offspring of schizophrenics. Fetal and neonatal deaths. Arch. Gen. Psychiatry, 1975, 32(2), 200-211.
[http://dx.doi.org/10.1001/archpsyc.1975.01760200064006] [PMID: 234727]
[17]
Milkovich, L.; van den Berg, B.J. An evaluation of the teratogenicity of certain antinauseant drugs. Am. J. Obstet. Gynecol., 1976, 125(2), 244-248.
[http://dx.doi.org/10.1016/0002-9378(76)90601-3] [PMID: 773181]
[18]
McKeigue, P.M.; Lamm, S.H.; Linn, S.; Kutcher, J.S. Bendectin and birth defects: I. A meta‐analysis of the epidemiologic studies. Teratology, 1994, 50(1), 27-37.
[http://dx.doi.org/10.1002/tera.1420500105] [PMID: 7974252]
[19]
Slone, D.; Siskind, V.; Heinonen, O.P.; Monson, R.R.; Kaufman, D.W.; Shapiro, S. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am. J. Obstet. Gynecol., 1977, 128(5), 486-488.
[http://dx.doi.org/10.1016/0002-9378(77)90029-1] [PMID: 879206]
[20]
Godet, P.F.; Marie-Cardine, M. Neuroleptiques, schizophrénie et grossesse. Etude épidémiologique et tératologique. Encephale, 1991, 17(6), 543-547.
[PMID: 1687216]
[21]
Sharma, J.B.; Sharma, S. Role of thioridazine in unexplained infertility. Int. J. Gynaecol. Obstet., 1992, 37(1), 37-41.
[http://dx.doi.org/10.1016/0020-7292(92)90975-O] [PMID: 1346599]
[22]
Goldstein, D.J.; Corbin, L.A.; Fung, M.C. Olanzapine-exposed pregnancies and lactation: Early experience. J. Clin. Psychopharmacol., 2000, 20(4), 399-403.
[http://dx.doi.org/10.1097/00004714-200008000-00002] [PMID: 10917399]
[23]
Diav-Citrin, O.; Shechtman, S.; Ornoy, S.; Arnon, J.; Schaefer, C.; Garbis, H.; Clementi, M.; Ornoy, A. Safety of haloperidol and penfluridol in pregnancy: A multicenter, prospective, controlled study. J. Clin. Psychiatry, 2005, 66(3), 317-322.
[http://dx.doi.org/10.4088/JCP.v66n0307] [PMID: 15766297]
[24]
McKenna, K.; Koren, G.; Tetelbaum, M.; Wilton, L.; Shakir, S.; Diav-Citrin, O.; Levinson, A.; Zipursky, R.B.; Einarson, A. Pregnancy outcome of women using atypical antipsychotic drugs: A prospective comparative study. J. Clin. Psychiatry, 2005, 66(4), 444-449.
[http://dx.doi.org/10.4088/JCP.v66n0406] [PMID: 15816786]
[25]
Reis, M.; Källén, B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J. Clin. Psychopharmacol., 2008, 28(3), 279-288.
[http://dx.doi.org/10.1097/JCP.0b013e318172b8d5] [PMID: 18480684]
[26]
Babu, G.N.; Desai, G.; Tippeswamy, H.; Chandra, P.S. Birth weight and use of olanzapine in pregnancy: A prospective comparative study. J. Clin. Psychopharmacol., 2010, 30(3), 331-332.
[http://dx.doi.org/10.1097/JCP.0b013e3181db8734] [PMID: 20473073]
[27]
Gilad, O.; Merlob, P.; Stahl, B.; Klinger, G. Outcome of infants exposed to olanzapine during breastfeeding. Breastfeed. Med., 2011, 6(2), 55-58.
[http://dx.doi.org/10.1089/bfm.2010.0027] [PMID: 21034242]
[28]
Habermann, F.; Fritzsche, J.; Fuhlbrück, F.; Wacker, E.; Allignol, A.; Weber-Schoendorfer, C.; Meister, R.; Schaefer, C. Atypical antipsychotic drugs and pregnancy outcome: A prospective, cohort study. J. Clin. Psychopharmacol., 2013, 33(4), 453-462.
[http://dx.doi.org/10.1097/JCP.0b013e318295fe12] [PMID: 23764684]
[29]
Sadowski, A.; Todorow, M.; Yazdani Brojeni, P.; Koren, G.; Nulman, I. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: A cohort study. BMJ Open, 2013, 3(7), e003062.
[http://dx.doi.org/10.1136/bmjopen-2013-003062] [PMID: 23852139]
[30]
Bellet, F.; Beyens, M.N.; Bernard, N.; Beghin, D.; Elefant, E.; Vial, T. Exposure to aripiprazole during embryogenesis: A prospective multicenter cohort study. Pharmacoepidemiol. Drug Saf., 2015, 24(4), 368-380.
[http://dx.doi.org/10.1002/pds.3749] [PMID: 25683615]
[31]
Cohen, L.S.; Viguera, A.C.; McInerney, K.A.; Freeman, M.P.; Sosinsky, A.Z.; Moustafa, D.; Marfurt, S.P.; Kwiatkowski, M.A.; Murphy, S.K.; Farrell, A.M.; Chitayat, D.; Hernández-Díaz, S. Reproductive safety of second-generation antipsychotics: Current data from the massachusetts general hospital national pregnancy registry for atypical antipsychotics. Am. J. Psychiatry, 2016, 173(3), 263-270.
[http://dx.doi.org/10.1176/appi.ajp.2015.15040506] [PMID: 26441156]
[32]
Montastruc, F.; Salvo, F.; Arnaud, M.; Bégaud, B.; Pariente, A. Signal of gastrointestinal congenital malformations with antipsychotics after minimising competition bias: A disproportionality analysis using data from Vigibase. Drug Saf., 2016, 39(7), 689-696.
[http://dx.doi.org/10.1007/s40264-016-0413-1] [PMID: 26961536]
[33]
Petersen, I.; McCrea, R.L.; Sammon, C.J.; Osborn, D.P.J.; Evans, S.J.; Cowen, P.J.; Freemantle, N.; Nazareth, I. Risks and benefits of psychotropic medication in pregnancy: Cohort studies based on UK electronic primary care health records. Health Technol. Assess., 2016, 20(23), 1-176.
[http://dx.doi.org/10.3310/hta20230] [PMID: 27029490]
[34]
Petersen, I.; Sammon, C.J.; McCrea, R.L.; Osborn, D.P.J.; Evans, S.J.; Cowen, P.J.; Nazareth, I. Risks associated with antipsychotic treatment in pregnancy: Comparative cohort studies based on electronic health records. Schizophr. Res., 2016, 176(2-3), 349-356.
[http://dx.doi.org/10.1016/j.schres.2016.07.023] [PMID: 27484686]
[35]
Huybrechts, K.F.; Hernández-Díaz, S.; Patorno, E.; Desai, R.J.; Mogun, H.; Dejene, S.Z.; Cohen, J.M.; Panchaud, A.; Cohen, L.; Bateman, B.T. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry, 2016, 73(9), 938-946.
[http://dx.doi.org/10.1001/jamapsychiatry.2016.1520] [PMID: 27540849]
[36]
Hatters, F.S.; Moller-Olsen, C.; Prakash, C.; North, A. Atypical antipsychotic use and outcomes in an urban maternal mental health service. Int. J. Psychiatry Med., 2016, 51(6), 521-533.
[http://dx.doi.org/10.1177/0091217417696739] [PMID: 28629296]
[37]
Shin, Y.J.; Choi, J.S.; Ahn, H.K.; Ryu, H.M.; Kim, M.Y.; Han, J.Y. Pregnancy outcomes in women reporting ingestion of levosulpiride in early pregnancy. J. Obstet. Gynaecol., 2017, 37(8), 992-995.
[http://dx.doi.org/10.1080/01443615.2017.1312307] [PMID: 28631490]
[38]
Onken, M.; Mick, I.; Schaefer, C. Paliperidone and pregnancy: An evaluation of the German Embryotox database. Arch. Women Ment. Health, 2018, 21(6), 657-662.
[http://dx.doi.org/10.1007/s00737-018-0828-z] [PMID: 29569043]
[39]
Galbally, M.; Frayne, J.; Watson, S.J.; Snellen, M. Aripiprazole and pregnancy: A retrospective, multicentre study. J. Affect. Disord., 2018, 238, 593-596.
[http://dx.doi.org/10.1016/j.jad.2018.06.004] [PMID: 29957476]
[40]
Cohen, L.S.; Góez-Mogollón, L.; Sosinsky, A.Z.; Savella, G.M.; Viguera, A.C.; Chitayat, D.; Hernández-Díaz, S.; Freeman, M.P. Risk of major malformations in infants following first-trimester exposure to quetiapine. Am. J. Psychiatry, 2018, 175(12), 1225-1231.
[http://dx.doi.org/10.1176/appi.ajp.2018.18010098] [PMID: 30111186]
[41]
Anderson, K.N.; Ailes, E.C.; Lind, J.N.; Broussard, C.S.; Bitsko, R.H.; Friedman, J.M.; Bobo, W.V.; Reefhuis, J.; Tinker, S.C. Atypical antipsychotic use during pregnancy and birth defect risk: National Birth Defects Prevention Study, 1997–2011. Schizophr. Res., 2020, 215, 81-88.
[http://dx.doi.org/10.1016/j.schres.2019.11.019] [PMID: 31761471]
[42]
Ellfolk, M.; Leinonen, M.K.; Gissler, M.; Lahesmaa-Korpinen, A.M.; Saastamoinen, L.; Nurminen, M.L.; Malm, H. Second-generation antipsychotics and pregnancy complications. Eur. J. Clin. Pharmacol., 2020, 76(1), 107-115.
[http://dx.doi.org/10.1007/s00228-019-02769-z] [PMID: 31680189]
[43]
Ellfolk, M.; Leinonen, M.K.; Gissler, M.; Kiuru-Kuhlefelt, S.; Saastamoinen, L.; Malm, H. Second-generation antipsychotic use during pregnancy and risk of congenital malformations. Eur. J. Clin. Pharmacol., 2021, 77(11), 1737-1745.
[http://dx.doi.org/10.1007/s00228-021-03169-y] [PMID: 34100993]
[44]
Freeman, M.P.; Viguera, A.C.; Góez-Mogollón, L.; Young, A.V.; Caplin, P.S.; McElheny, S.A.; Church, T.R.; Chitayat, D.; Hernández-Díaz, S.; Cohen, L.S. Reproductive safety of aripiprazole: Data from the massachusetts general hospital national pregnancy registry for atypical antipsychotics. Arch. Women Ment. Health, 2021, 24(4), 659-667.
[http://dx.doi.org/10.1007/s00737-021-01115-6] [PMID: 33710399]
[45]
Viguera, A.C.; Freeman, M.P.; Góez-Mogollón, L.; Sosinsky, A.Z.; McElheny, S.A.; Church, T.R.; Young, A.V.; Caplin, P.S.; Chitayat, D.; Hernández-Díaz, S.; Cohen, L.S. Reproductive safety of second-generation antipsychotics: updated data from the massachusetts general hospital national pregnancy registry for atypical antipsychotics. J. Clin. Psychiatry, , 2021, 82(4), 20m13745.
[http://dx.doi.org/10.4088/JCP.20m13745]
[46]
Nguyen, T.; Frayne, J.; Watson, S.; Lebedevs, T.; Teoh, S.; Galbally, M. Long-acting injectable antipsychotic treatment during pregnancy: Outcomes for women at a tertiary maternity hospital. Psychiatry Res., 2022, 313, 114614.
[http://dx.doi.org/10.1016/j.psychres.2022.114614] [PMID: 35576628]
[47]
Yakuwa, N.; Takahashi, K.; Anzai, T.; Ito, N.; Goto, M.; Koinuma, S.; Uno, C.; Suzuki, T.; Watanabe, O.; Yamatani, A.; Murashima, A. Pregnancy outcomes with exposure to second-generation antipsychotics during the first trimester. Clin. Psychiatry, 2022, 83(4), 21m14081.
[http://dx.doi.org/10.4088/JCP.21m14081]
[48]
Hálfdánarson, Ó.; Cohen, J.M.; Karlstad, Ø.; Cesta, C.E.; Bjørk, M.H.; Håberg, S.E.; Einarsdóttir, K.; Furu, K.; Gissler, M.; Hjellvik, V.; Kieler, H.; Leinonen, M.K.; Nørgaard, M.; Öztürk Esen, B.; Ulrichsen, S.P.; Reutfors, J.; Zoega, H. Antipsychotic use in pregnancy and risk of attention/deficit-hyperactivity disorder and autism spectrum disorder: A Nordic cohort study. Evid. Based Ment. Health, 2022, 25(2), 54-62.
[http://dx.doi.org/10.1136/ebmental-2021-300311] [PMID: 34810174]
[49]
Straub, L.; Hernández-Díaz, S.; Bateman, B.T.; Wisner, K.L.; Gray, K.J.; Pennell, P.B.; Lester, B.; McDougle, C.J.; Suarez, E.A.; Zhu, Y.; Zakoul, H.; Mogun, H.; Huybrechts, K.F. Association of antipsychotic drug exposure in pregnancy with risk of neurodevelopmental disorders: A National Birth Cohort Study. JAMA Intern. Med., 2022, 182(5), 522-533.
[http://dx.doi.org/10.1001/jamainternmed.2022.0375] [PMID: 35343998]
[50]
Huybrechts, K.F.; Straub, L.; Karlsson, P.; Pazzagli, L.; Furu, K.; Gissler, M.; Hernandez-Diaz, S.; Nørgaard, M.; Zoega, H.; Bateman, B.T.; Cesta, C.E.; Cohen, J.M.; Leinonen, M.K.; Reutfors, J.; Selmer, R.M.; Suarez, E.A.; Ulrichsen, S.P.; Kieler, H. Association of in utero antipsychotic medication exposure with risk of congenital malformations in Nordic countries and the US. JAMA Psychiatry, 2023, 80(2), 156-166.
[http://dx.doi.org/10.1001/jamapsychiatry.2022.4109] [PMID: 36477338]
[51]
Cohen, L.S.; Church, T.R.; Freeman, M.P.; Gaccione, P.; Caplin, P.S.; Kobylski, L.A.; Arakelian, M.; Rossa, E.T.; Chitayat, D.; Hernández-Díaz, S.; Viguera, A.C. Reproductive safety of lurasidone and quetiapine: Update from the national pregnancy registry for psychiatric medications. J. Womens Health , 2023, 32(4), 452-462.
[http://dx.doi.org/10.1089/jwh.2022.0310] [PMID: 36716275]
[52]
Viguera, A.C.; Freeman, M.P.; Kobylski, L.A.; Rossa, E.T.; Gaccione, P.; Chitayat, D.; Hernández-Díaz, S.; Cohen, L.S. Risk of major malformations following first-trimester exposure to olanzapine: Preliminary data from the Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications. J. Clin. Psychopharmacol., 2023, 43(2), 106-112.
[http://dx.doi.org/10.1097/JCP.0000000000001665] [PMID: 36825887]
[53]
Liu, X.; Kolding, L.; Momen, N.; Gasse, C.; Pedersen, L.H. Maternal antipsychotic use during pregnancy and congenital malformations. Am. J. Obstet. Gynecol. MFM, 2023, 5(6), 100950.
[http://dx.doi.org/10.1016/j.ajogmf.2023.100950] [PMID: 37015311]
[54]
Schrijver, L.; Robakis, T.K.; Kamperman, A.M.; Bijma, H.; Honig, A.; van Kamp, I.L.; Hoogendijk, W.J.G.; Bergink, V.; Poels, E.M.P. Neurodevelopment in school‐aged children after intrauterine exposure to antipsychotics. Acta Psychiatr. Scand., 2023, 147(1), 43-53.
[http://dx.doi.org/10.1111/acps.13517] [PMID: 36333825]
[55]
Idänpään-Heikkilä, J.; Alhava, E.; Olkinuora, M.; Palva, I. Letter: Clozapine and agranulocytosis. Lancet, 1975, 306(7935), 611.
[http://dx.doi.org/10.1016/S0140-6736(75)90206-8] [PMID: 51442]
[56]
Meltzer, H.Y.; Bastani, B.; Ramirez, L.; Matsubara, S. Clozapine: New research on efficacy and mechanism of action. Eur. Arch. Psychiatry Neurol. Sci., 1989, 238(5-6), 332-339.
[http://dx.doi.org/10.1007/BF00449814] [PMID: 2569975]
[57]
Perrault, G.; Schoemaker, H.; Scatton, B. Place de l’amisulpride dans la classe des neuroleptiques atypiques. Encephale, 1996, 22(Spec No 2), 3-8.
[PMID: 8767034]
[58]
Citrome, L.; Holt, R.I.G.; Walker, D.J.; Hoffmann, V.P. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin. Drug Investig., 2011, 31(7), 455-482.
[http://dx.doi.org/10.2165/11589060-000000000-00000] [PMID: 21495734]
[59]
Lambert, T.J.R. Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder. Evid. Based Ment. Health, 2009, 12(2), 50.
[http://dx.doi.org/10.1136/ebmh.12.2.50] [PMID: 19395609]
[60]
Tyrrell, J.; Richmond, R.C.; Palmer, T.M.; Feenstra, B.; Rangarajan, J.; Metrustry, S.; Cavadino, A.; Paternoster, L.; Armstrong, L.L.; De Silva, N.M.G.; Wood, A.R.; Horikoshi, M.; Geller, F.; Myhre, R.; Bradfield, J.P.; Kreiner-Møller, E.; Huikari, V.; Painter, J.N.; Hottenga, J.J.; Allard, C.; Berry, D.J.; Bouchard, L.; Das, S.; Evans, D.M.; Hakonarson, H.; Hayes, M.G.; Heikkinen, J.; Hofman, A.; Knight, B.; Lind, P.A.; McCarthy, M.I.; McMahon, G.; Medland, S.E.; Melbye, M.; Morris, A.P.; Nodzenski, M.; Reichetzeder, C.; Ring, S.M.; Sebert, S.; Sengpiel, V.; Sørensen, T.I.A.; Willemsen, G.; de Geus, E.J.C.; Martin, N.G.; Spector, T.D.; Power, C.; Järvelin, M.R.; Bisgaard, H.; Grant, S.F.A.; Nohr, E.A.; Jaddoe, V.W.; Jacobsson, B.; Murray, J.C.; Hocher, B.; Hattersley, A.T.; Scholtens, D.M.; Davey Smith, G.; Hivert, M.F.; Felix, J.F.; Hyppönen, E.; Lowe, W.L., Jr; Frayling, T.M.; Lawlor, D.A.; Freathy, R.M. Genetic evidence for causal relationships between maternal obesity-related traits and birth weight. JAMA, 2016, 315(11), 1129-1140.
[http://dx.doi.org/10.1001/jama.2016.1975] [PMID: 26978208]
[61]
Schmidt, M.; Schmidt, S.A.J.; Sandegaard, J.L.; Ehrenstein, V.; Pedersen, L.; Sørensen, H.T. The danish national patient registry: A review of content, data quality, and research potential. Clin. Epidemiol., 2015, 7, 449-490.
[http://dx.doi.org/10.2147/CLEP.S91125] [PMID: 26604824]
[62]
Lynge, E.; Sandegaard, J.L.; Rebolj, M. The danish national patient register. Scand. J. Public Health,, 2011, 39(7_suppl)(Suppl.), 30-33.
[http://dx.doi.org/10.1177/1403494811401482] [PMID: 21775347]
[63]
Cohen, L.S.; Viguera, A.C.; McInerney, K.A.; Kwiatkowski, M.A.; Murphy, S.K.; Lemon, E.L.; Hernández-Díaz, S. Establishment of the national pregnancy registry for atypical antipsychotics. J. Clin. Psychiatry, 2015, 76(7), 986-989.
[http://dx.doi.org/10.4088/JCP.14br09418] [PMID: 25939066]
[64]
Vari, I.S.; Balkau, B.; Kettaneh, A.; André, P.; Tichet, J.; Fumeron, F.; Caces, E.; Marre, M.; Grandchamp, B.; Ducimetière, P. Ferritin and transferrin are associated with metabolic syndrome abnormalities and their change over time in a general population: Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care, 2007, 30(7), 1795-1801.
[http://dx.doi.org/10.2337/dc06-2312] [PMID: 17416791]
[65]
Musenga, A.; Saracino, M.; Sani, G.; Raggi, M. Antipsychotic and antiepileptic drugs in bipolar disorder: The importance of therapeutic drug monitoring. Curr. Med. Chem., 2009, 16(12), 1463-1481.
[http://dx.doi.org/10.2174/092986709787909604] [PMID: 19355900]
[66]
Wang, Z.; Brauer, R.; Man, K.K.C.; Alfageh, B.; Mongkhon, P.; Wong, I.C.K. Prenatal exposure to antipsychotic agents and the risk of congenital malformations in children: A systematic review and meta‐analysis. Br. J. Clin. Pharmacol., 2021, 87(11), 4101-4123.
[http://dx.doi.org/10.1111/bcp.14839] [PMID: 33772841]
[67]
Hillemacher, T.; Simen, S.; Rehme, M.K.; Frieling, H. Antipsychotics during pregnancy: A systematic review. Nervenarzt, 2021, 92(5), 494-500.
[http://dx.doi.org/10.1007/s00115-020-01006-8]
[68]
Gentile, S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr. Bull., 2010, 36(3), 518-544.
[http://dx.doi.org/10.1093/schbul/sbn107] [PMID: 18787227]
[69]
Gentile, S.; Fusco, M.L. Schizophrenia and motherhood. Psychiatry Clin. Neurosci., 2019, 73(7), 376-385.
[http://dx.doi.org/10.1111/pcn.12856] [PMID: 31026107]
[70]
Oyebode, F.; Rastogi, A.; Berrisford, G.; Coccia, F. Psychotropics in pregnancy: Safety and other considerations. Pharmacol. Ther., 2012, 135(1), 71-77.
[http://dx.doi.org/10.1016/j.pharmthera.2012.03.008] [PMID: 22483705]
[71]
Coughlin, C.G.; Blackwell, K.A.; Bartley, C.; Hay, M.; Yonkers, K.A.; Bloch, M.H. Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy. Obstet. Gynecol., 2015, 125(5), 1224-1235.
[http://dx.doi.org/10.1097/AOG.0000000000000759] [PMID: 25932852]
[72]
Centorrino, F.; Fogarty, K.V.; Sani, G.; Salvatore, P.; Cincotta, S.L.; Hennen, J.; Guzzetta, F.; Talamo, A.; Saadeh, M.G.; Baldessarini, R.J. Use of combinations of antipsychotics: McLean Hospital inpatients, 2002. Hum. Psychopharmacol., 2005, 20(7), 485-492.
[http://dx.doi.org/10.1002/hup.719] [PMID: 16116665]
[73]
Centorrino, F.; Fogarty, K.V.; Sani, G.; Salvatore, P.; Cimbolli, P.; Baldessarini, R.J. Antipsychotic drug use: McLean Hospital, 2002. Hum. Psychopharmacol., 2005, 20(5), 355-358.
[http://dx.doi.org/10.1002/hup.700] [PMID: 15957153]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy